Retraction Notice to “Evaluation of the Treatment Strategies on Patient-Derived Xenograft Mice of Human Breast Tumor” [Eur. J. Pharmacol. 889 (2020) 173605] (European Journal of Pharmacology (2020) 889, (S001429992030697x), (10.1016/J.Ejphar.2020.173605)) Publisher Pubmed



Khalighfard S¹ ; Alizadeh AM^{2, 3} ; Poorkhani A⁴ ; Motahari M⁵ ; Tahmasebifar A⁵ ; Omranipour R² ; Keshavarz P⁶ ; Haddad P¹
Source: European Journal of Pharmacology Published:2024

Abstract

This article has been retracted at the request of Editor-in-Chief. The authors requested to publish a corrigendum to rectify mistakenly used images in Figures 1 and 4, which contain identical parts to the images in Figure 1 of another article by the same author group (Khori et al., 2018 Peptide, 107, 54–60, 10.1016/j.peptides.2018.07.007). The editor found more concerns about the integrity of the images shown in Figures 4, based on the in-house image analysis and reported suspected image duplications. Furthermore, in-house image analysis revealed that, in Figure 6, the Western blot subfigures for BCL2 (ADR + Cyclo and ADR + Cyclo + Tax) appear identical to these of Caspase 3 (Control and TAM), but the figure has been rotated 180°. The Editor asked the authors for an explaination, but a satisfactory answer was not provided. Due to the above concerns, the Editor decided to retract the paper. © 2024 Elsevier B.V.